BIO vs BVS: fair value comparison
Bio-Rad Laboratories, Inc. and Bioventus Inc. · Updated 2026-09-07
BIO currently screens as overvalued while BVS screens as fairly valued. Within Healthcare, BVS currently sits closer to the top of our discount ranking. BIO carries the stronger quality grade.
| BIO | BVS | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $330.01 | $13.47 |
| 12-month range | $256.55–$380.96 | $6.56–$13.47 |
| Sector rank | #88 of 113 Healthcare | #85 of 113 Healthcare |
| Quality grade | B | D |
| Leverage | Low | Moderate |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: BIO fair value analysis · BVS fair value analysis